secwatch / observer
8-K filed January 16, 2025, 6:59 PM ET CIK 0001785592
other material confidence high sentiment negative materiality 0.90

Leafly receives Nasdaq delisting notice; stock to move to OTC Pink; convertible notes extended to July 2025

Leafly Holdings, Inc. /DE

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0000950170-25-006032
form_type
8-K
ticker
null
cik
0001785592
company_name
Leafly Holdings, Inc. /DE
filed_at
2025-01-16T23:59:59+00:00
discovered_at
2026-05-14T18:03:04.852313+00:00
generated_at
2026-05-28T00:11:59.022707+00:00
sec_items
["1.01", "3.01", "3.03", "7.01", "9.01"]
event_type
other_material
sentiment
negative
materiality_score
0.9
calibrated_materiality_score
0.9
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0000950170-25-006032
json_url
https://secwatch.observer/filing/0000950170-25-006032.json
markdown_url
https://secwatch.observer/filing/0000950170-25-006032.md
text_url
https://secwatch.observer/filing/0000950170-25-006032.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1785592/000095017025006032/0000950170-25-006032-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1785592/000095017025006032/lfly-20250115.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null

Source-grounded claims

ca081e5723ee54e712cf593e676b7734447e5397

Leafly Holdings, Inc. /DE received a nasdaq delisting notice notice regarding other (rules 5550(b)).

January 15, 2025, the Company received written notification (the “Delisting Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s common

SEC 8-K Item 3.01 confidence 0.9 SEC evidence

Comparable filings

DRCT

DRCT enters $50M equity line with Roth, terminates New Circle ELOC, receives Nasdaq delisting notice

Direct Digital Holdings, Inc. April 28, 2026, 7:59 PM ET other_material Items 1.01, 1.02, 3.01, 3.03, 5.03, 9.01

same fact type: exchange_compliance_notice same SEC item: 1.01, 3.01, 3.03, 9.01 same event type: other_material similar materiality

This filing

January 15, 2025, the Company received written notification (the “Delisting Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s common

Comparable filing

April 23, 2026, the Company received an Additional Staff Delisting Determination Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”), notifying the Company that it is not in comp

Filing page SEC filing

PMI

Picard Medical Q1 revenue up 85% to $1.2M; reports $1.4M negative equity, NYSE listing notices

Picard Medical, Inc. May 21, 2026, 4:15 PM ET other_material Items 2.02, 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: other_material similar materiality

This filing

January 15, 2025, the Company received written notification (the “Delisting Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s common

Comparable filing

reviously disclosed, on May 8, 2026, the Company received a notice that it was not in compliance with Section 1003(a)(ii) (the “May 8 Notice,” and together with the May 15 Notice, the “ Notices ”). In connection with the

Filing page SEC filing

BKYI

BIO-key receives Nasdaq delisting notice; stock to move to OTC Markets on May 13

BIO KEY INTERNATIONAL INC May 12, 2026, 4:46 PM ET other_material Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: other_material similar materiality

This filing

January 15, 2025, the Company received written notification (the “Delisting Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s common

Comparable filing

May 6, 2026, BIO-key International, Inc. (the “ Company ”) received notice from the staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) stating that the Company had not regained compliance with Nasdaq Listing Rule 5550(a)

Filing page SEC filing

PMI

Picard Medical raises $5M in public offering, receives NYSE American delisting notice for low equity

Picard Medical, Inc. May 11, 2026, 5:08 PM ET other_material Items 1.01, 3.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 1.01, 3.01, 9.01 same event type: other_material similar materiality

This filing

January 15, 2025, the Company received written notification (the “Delisting Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s common

Comparable filing

May 8, 2026, the Company received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Notice states that the Company reported a stockholders’ equity of approximately $3.8 million as of

Filing page SEC filing

ADTX

Aditxt receives Nasdaq deficiency for negative equity; delisting hearing set for June 11

Aditxt, Inc. May 29, 2026, 4:21 PM ET other_material Items 3.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 9.01 same event type: other_material similar materiality

This filing

January 15, 2025, the Company received written notification (the “Delisting Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s common

Comparable filing

May 27, 2026, Aditxt, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the stockholders’ equity of $(35,174,386) reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), the Company no longer satisfies the minimum stockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”). The Letter further

Filing page SEC filing

LIMN

Liminatus Pharma receives Nasdaq delisting notice; appeals filed

Liminatus Pharma, Inc. May 27, 2026, 4:30 PM ET other_material Items 3.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 9.01 same event type: other_material similar materiality

This filing

January 15, 2025, the Company received written notification (the “Delisting Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s common

Comparable filing

May 20, 2026, the Company received a notice from Nasdaq stating that the Company had not regained compliance with the MVLS Rule and the MVPHS Rule. Accordingly, its securities will be delisted from The Nasdaq Global Mark

Filing page SEC filing

XXI

Tether International acquires SoftBank's stake in Twenty One Capital; board members resign

Twenty One Capital, Inc. May 20, 2026, 8:49 AM ET other_material Items 1.02, 3.01, 5.02, 8.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 9.01 same event type: other_material similar materiality

This filing

January 15, 2025, the Company received written notification (the “Delisting Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s common

Comparable filing

o independent directors, the minimum number required during the transition period for compliance with Section 303A.07(a) of the NYSE Listed Company Manual, as provided in Section 303A.00 of the NYSE Listed Company Manual

Filing page SEC filing

GCTK

Glucotrack receives second Nasdaq delisting notice; plans to appeal by May 18

Glucotrack, Inc. May 15, 2026, 4:45 PM ET other_material Items 3.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 9.01 same event type: other_material similar materiality

This filing

January 15, 2025, the Company received written notification (the “Delisting Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s common

Comparable filing

May 15, 2026, the Company received a second letter from Nasdaq notifying the Company that its Form 10-Q for the period ended March 31, 2026, indicates that the Company no longer meets the $2,500,000 minimum stockholders’

Filing page SEC filing

Source: SEC EDGAR
accession 0000950170-25-006032

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.